Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Silence Therapeutics (SLN) EPS (Weighted Average and Diluted): 2022-2024

Historic EPS (Weighted Average and Diluted) for Silence Therapeutics (SLN) over the last 3 years, with Dec 2024 value amounting to -$0.33.

  • Silence Therapeutics' EPS (Weighted Average and Diluted) rose 40.00% to -$0.15 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.15, marking a year-over-year increase of 45.95%. This contributed to the annual value of -$0.33 for FY2024, which is 32.65% up from last year.
  • Per Silence Therapeutics' latest filing, its EPS (Weighted Average and Diluted) stood at -$0.33 for FY2024, which was up 32.65% from -$0.49 recorded in FY2023.
  • Silence Therapeutics' EPS (Weighted Average and Diluted)'s 5-year high stood at -$0.33 during FY2024, with a 5-year trough of -$0.52 in FY2022.
  • For the 3-year period, Silence Therapeutics' EPS (Weighted Average and Diluted) averaged around -$0.45, with its median value being -$0.49 (2023).
  • Its EPS (Weighted Average and Diluted) has fluctuated over the past 5 years, first dropped by 5.77% in 2023, then surged by 32.65% in 2024.
  • Silence Therapeutics' EPS (Weighted Average and Diluted) (MRY) stood at -$0.52 in 2022, then increased by 5.77% to -$0.49 in 2023, then surged by 32.65% to -$0.33 in 2024.
  • Its EPS (Weighted Average and Diluted) stands at -$0.33 for FY2024, versus -$0.49 for FY2023 and -$0.52 for FY2022.